CASE OF SUCCESSFULL TREATMENT OF SQUAMOUSCELL CARCINOMA IIIA (IMMUNOTHERAPY + SURGICAL RESECTION), FOLLOWED BY VATS S6 SEGMENTECTOMY FOR METACHRONOUS SQUAMOUS-CELL CARCINOMA IA IN CONTRALATERAL LUNG
Vol. 66 No. 3 (2020), CLINICAL CASE
Vol. 66 No. 3 (2020)

CASE OF SUCCESSFULL TREATMENT OF SQUAMOUSCELL CARCINOMA IIIA (IMMUNOTHERAPY + SURGICAL RESECTION), FOLLOWED BY VATS S6 SEGMENTECTOMY FOR METACHRONOUS SQUAMOUS-CELL CARCINOMA IA IN CONTRALATERAL LUNG

CLINICAL CASE
https://doi.org/10.37469/0507-3758-2020-66-3-291-295
Published 01.03.2020
Andrey Petrov
St.Petersburg University, State-Financed Health Institution «City Hospital № 2»
M. Atyukov
State-Financed Health Institution «City Hospital № 2»
O. Zhemchugova
St.Petersburg University
Irina Zemtsova
St.Petersburg University, State-Financed Health Institution «City Hospital № 2»
M. Yanchii
N. N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia
Petr Yablonskiy
St.Petersburg University, State-Financed Health Institution «City Hospital № 2»
PDF (Русский)

Keywords

ЛЕЧЕНИЕ IIIA СТАДИИ НМРЛ
NSCLC IIIA STAGE TREATMENT
NEOADJUVANT IMMUNOTHERAPY IN NSCLC
VATS SEGMENTECTOMY FOR NSCLC

How to Cite

Petrov, A., Atyukov, M., Zhemchugova, O., Zemtsova, I., Yanchii, M., & Yablonskiy, P. (2020). CASE OF SUCCESSFULL TREATMENT OF SQUAMOUSCELL CARCINOMA IIIA (IMMUNOTHERAPY + SURGICAL RESECTION), FOLLOWED BY VATS S6 SEGMENTECTOMY FOR METACHRONOUS SQUAMOUS-CELL CARCINOMA IA IN CONTRALATERAL LUNG. Voprosy Onkologii, 66(3), 291–295. https://doi.org/10.37469/0507-3758-2020-66-3-291-295
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

This unique clinical case illustrates several “hot topics” of NSCLC management in one patient including correct staging and treatment of IIIA(N2) stage, neoadjuvant immunotherapy with phenomenon of pseudoprogression, VATS segmentectomy for peripheral stage IA NSCLC with good outcome.
https://doi.org/10.37469/0507-3758-2020-66-3-291-295
PDF (Русский)

References

Tsitsias T., Boulemden A., Ang K. et al. The N2 paradox: similar out-comes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer. Eur J Cardiothorac Surg 2014; 45: 882-887.

van Meerbeeck J.P., Kramer G.W., Van Schil P.E. et al. Randomized controlled trial of resection versus radio therapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99: 442-450.

Барчук А.С., Левченко Е.В., Арсеньев А.И. и др. Актуальные вопросы комбинированного лечения рака легкого. Вопросы онкологии; 2012. Т. 58. № 2. С. 253259.

National Comprehensive Cancer Network. Lung cancer (2019). Version 7.2019, 10/10/19 https://www.nccn.org/ professionals/physician_gls/pdf

Postmus P.E., Kerr K.M., Oudkerk M. et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology. 2017, Volume 28, Issue suppl_4, Pages iv1-iv21.

Chaft Jamie E., Valerie Rusch, Michelle S. Ginsberg et al. Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-Small-Cell Lung Cancers. Journal of Thoracic Oncology. 2013. 8, no. 8: 1084-1090. DOI: 10.1097/jto.0b013e31829923ec

Provencio-Pulla Mariano, Ernest Nadal-Alforja, Manuel Cobo et al. Neoadjuvant Chemo/immunotherapy for the Treatment of Stages IIIA Resectable Non-Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory study-NADIM Study-SLCG. Journal of Clinical Oncology. 2018, 36, no. 15_suppl: 8521-8521.

Bott Matthew J., Stephen C. Yang, Bernard J. Park et al. Initial Results of Pulmonary Resection after Neoadjuvant Nivolumab in Patients with Resectable Non-small Cell Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery. 2019, 158, no. 1: 269-276. DOI: 10.1016/j.jtcvs.2018.11.124

Blasberg Justin D., Harvey I. Pass, Jessica S. Donington. Sublobar Resection: A Movement from the Lung Cancer Study Group. Journal of Thoracic Oncology. 2010, 5, no. 10: 1583-1593.

Nakamura K., H. Saji, R. Nakajima et al. A Phase III Randomized Trial of Lobectomy Versus Limited Resection for Small-Sized Peripheral Non-Small Cell Lung Cancer (JCOG0802/WJOG4607L). Japanese Journal of Clinical Oncology. 2009, 40, no. 3: 271-274.

Merlano Marco, Marcella Occelli, Ornella Garrone. Immune-Related Response Criteria: Light and Shadows. ESMO Open. 2016, 1, no. 4: e000082. DOI: 10.1136/es-moopen-2016-000082

Hochmair Maximilian J., Sophia Schwab, Otto C. Burghuber et al. Symptomatic Pseudo-Progression Followed by Significant Treatment Response in Two Lung Cancer Patients Treated with Immunotherapy. Lung Cancer. 2017, 113: 4-6. DOI: 10.1016/j.lungcan.2017.08.020

Mayoral M., Castaner E., Gallardo X. et al. Pseudoprogresion Tumoral En El Tratamiento Inmunoterapico Con Nivolumab En El Cancer de Pulmon. Radiologia. 2019. DOI: 10.1016/j.rx.2019.05.004

Veluswamy Rajwanth R., Nicole Ezer, Grace Mhango et al. Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology. Journal of Clinical Oncology. 2015, 33, no. 30: 3447-3453. DOI: 10.1200/jco.2014.60.6624

Koike Terumoto, Akihiko Kitahara, Seijiro Sato et al. Lobectomy Versus Segmentectomy in Radiologically Pure Solid Small-Sized Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 2016, 101, no. 4: 1354-1360. DOI: 10.1016/j.athoracsur.2015.10.048

Yang Jie, Ming Liu, Jie Fan et al. Surgical Treatment of Metachronous Second Primary Lung Cancer. The Annals of Thoracic Surgery. 2014, 98, no. 4: 1192-1198. DOI: 10.1016/j.athoracsur.2014.05.050

Rzechonek Adam, Piotr Btasiak, Beata Muszczynska-Bernhard et al. Metachronous Lung Cancer: Clinical Characteristics and Effects of Surgical Treatment. Current Concepts in Medical Research and Practice. 2017: 9-17. DOI: 10.1007/5584_2017_82

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2020

Most read articles by the same author(s)